Journal article
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population
Imogen Walpole, Belinda Lee, Jeremy Shapiro, Benjamin Thomson, Lara Lipton, Sumitra Ananda, Val Usatoff, Sue-Ann Mclachlan, Brett Knowles, Adrian Fox, Rachel Wong, Prasad Cooray, Matthew Burge, Kate Clarke, Sharon Pattison, Mehrdad Nikfarjam, Niall Tebbutt, Marion Harris, Adnan Nagrial, Rob Zielinski Show all
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | WILEY | Published : 2023
DOI: 10.1111/ajco.13807
Abstract
Background: Use of neoadjuvant (NA) chemotherapy is recommended when pancreatic ductal adenocarcinoma (PDAC) is borderline resectable. Method: A retrospective analysis of consecutive patients with localized PDAC between January 2016 and March 2019 within the Australasian Pancreatic Cancer Registry (PURPLE, Pancreatic cancer: Understanding Routine Practice and Lifting End results) was performed. Clinicopathological characteristics, treatment, and outcome were analyzed. Overall survival (OS) comparison was performed using log-rank model and Kaplan–Meier analysis. Results: The PURPLE database included 754 cases with localised PDAC, including 148 (20%) cases with borderline resectable pancreatic..
View full abstractGrants
Funding Acknowledgements
Hemstritch Foundation; Pancare Foundation; Jreissati Foundation and Segal Foundation